RESUMEN

The aim of this study was to evaluate expression of receptor for IL-1 on tumor-derived cells. The in vivo acquisition of an expression of a receptor for Fc ç immunoglobulin on polyoma virus transformed cells has been established by us. We investigated whether a receptor for the IL-1 cytokine, like that for Fc gamma immunoglobulin, could also contribute to the heterogeneity of tumor cell population, as well as to its tumorigenic phenotype. Various clones of polyoma virus transformed 3T3 cells were passaged once in syngeneic mice and resulting tumors explanted and recultured. The expression of receptor for IL-1 was tested on in vitro maintained clones (designated C for culture) and on tumor derived clones (designated CTC - culture-tumor-culture). Expression was determined using a 125I radiolabeled ligand and confirmed by flow cytometry with anti-mouse IL-1 receptor (IL-1R) antibodies. Some CTC clones expressed a higher level of IL-1 receptor than others. A positive correlation between the level of IL-1R and a metastatic phenotype was established with some tumor derived cells. A high IL-1R expressing tumor cell population, sorted by flow cytometry, was considerably more metastatic than the sorted low IL-1 expressing cells. IL-1R expression by tumor derived cells may, contribute to the metastatic phenotype of a tumor cell population.

Asunto(s)

RESUMEN

Non immunohematopoietic murine tumor cells ectopically expressing Fc gamma RIIB1 (B1) were recently shown to express a higher tumorigenicity phenotype than cells not expressing this receptor. Utilizing a genetic approach we studied the possible contribution of a soluble form of B1 to tumor enhancement. A mutated form of the B1, lacking the cleavage site responsible for the generation of soluble B1 was produced using gene splicing by overlap extension PCR. A deletion confirmed by sequence analysis from 172 to 178 residues was generated. Stable transfectants expressed the B1 deleted form (B1 Delta) both as specific RNA and as a membrane protein receptor allowing a low level of ligand binding. The soluble form of B1 was undetectable in tissue culture supernatants of Bib transfected cells while it was present in supernatants of wild type B1-transfectants. Stable B1 Delta transfectants were significantly more tumorigenic than negative control transfectants. Tumor incidence was almost as high as that of intact B1 and lagged in the latency period before the appearance of palpable tumors. It is suggested that the soluble B1 has a minimal contribution to tumor enhancement.

RESUMEN

We have previously shown that Fc gamma receptor type II B1 (Fc(gamma)RIIB1), when expressed on non-lymphoid tumor cells, significantly enhanced their tumorigenic phenotype. This study elucidates the role of the intracellular domain of Fc(gamma)RIIB1 in the enhancement of the malignant phenotype of polyoma-transformed 3T3 cells. We investigated the tumorigenic potential conferred by different variants of the receptor: Fc(gamma)RIIB1, a full-length receptor (B1) whose intracellular region is encoded by exons 8, 9 and 10; Fc(gamma)RIIB2, a spliced variant (B2) whose cytoplasmic domain comprises exons 9 and 10 and lacks exon 8; and Fc(gamma)RIIB1-CT53, a deleted mutant whose cytoplasmic domain contains the fragment encoded by exon 8 alone. We have investigated various properties of cells transfected with each of the above variants: tumorigenicity in syngeneic mice, formation of colonies in soft agar, growth rate, production of soluble receptor and capping of the ligand-bound receptor. Results show that while the presence of exon 8 did not enhance growth rate in vitro or production of soluble Fc(gamma)R, it did enhance the tumorigenic phenotype of transfected cells (both in vivo and in vitro growth in soft agar). B1-expressing cells exhibited a significantly higher tumorigenic phenotype than B2 cells. The presence of exon 8 alone (CT53 mutant) conferred the transfected cells a higher tumorigenic phenotype than Fc(gamma)R-negative control cells but lower than intact B1 or B2 cells, indicating that the presence of B1-specific exon 8 is not sufficient but that the presence of an intact B1 intracellular domain is essential, for conferring the high tumorigenicity phenotype upon cells. We conclude that the capping, following ligand binding contributed by exon 8, and the function contributed by the specific localization of exons 9 and 10 in B1 cells may determine their malignant phenotype.

Asunto(s)

RESUMEN

The murine receptor for the Fc portion of IgG is a molecule expressed by cells of the immune system. This study suggests the hypothesis that Fc gamma receptor type II B I (Fc gamma RIIB I) functions as a progression-enhancing factor when expressed ectopically on non-lymphoid tumor cells. It has been shown previously that BALB/c 3T3 cells transformed in vitro with polyoma virus (PyV) do not express Fc gamma RII but acquire the expression of this receptor following an in vivo passage in syngeneic mice. The specific Fc gamma RII transcript present in tumor cells was identified in this report as Fc gamma RIIB I (BI). In order to determine whether or not the ectopically expressed Fc gamma RII plays a role in the progression of these transformed cells, PyV-transformed 3T3 cells were transfected with BI-cDNA. The BI transfected cells were tested for their ability to form local tumors in syngeneic mice, as compared to transfected cells which express the co-transfecting neomycine resistance (neores) DNA alone or together with the lacZ gene. Fc gamma RIIB I expressors exhibited a significantly higher tumorigenic phenotype than FcR-negative controls, though both types of cells exhibited the same growth curve in vitro. The ability of Fc gamma RIIB I to act as a potentially tumorgenicity-enhancing factor was also demonstrated as Fc gamma RII was expressed by tumor cells, originating from inoculated Fc gamma RIIB I-transfected cells, or from inoculation of a mixture of receptor-positive and -negative cells. B I-expressing cells dominated the tumor-cell population over non-expressors. This dominance strengthened the hypothesis that FcR plays a role in tumor progression in vivo.

Asunto(s)

RESUMEN

Cloned BALB/c 3T3 cells transformed in vitro with polyoma virus and maintained in culture (C cells) were compared with respect to their ability to form experimental metastases, with cells from the same clones that were passaged subcutaneously in vivo (CTC cells), thereby gaining a high tumorigenicity phenotype. No correlation was found between a high subcutaneous tumorigenicity potential or the progression state of these cells, and their capacity to form experimental metastases. Both cell types were also tested for their ability to release heparan sulfate degradation products from a naturally produced, sulfate-labeled extracellular matrix (ECM). Whereas the in vitro maintained C cells did not express an endo-beta-D-glucuronidase (heparanase) activity, some of the in vivo passaged CTC cells expressed such an activity. No strict correlation was found, however, between heparanase activity and the ability of CTC cells from individual tumors to form experimental metastases. However, A9 CTC 220 cells which produced a large number of lung metastases also expressed a high heparanase activity. Both heparanase and lung colonization by A9 CTC 220 cells were inhibited to a large extent by heparin, suggesting the involvement of heparanase in the extravasation of these highly metastatic cells. A9 CTC 220 cells were found to release basic fibroblast growth factor (bFGF) from ECM. This release was partially inhibited by carrageenan lambda which also completely inhibited the heparanase activity expressed by these cells. The in vivo acquisition of heparanase activity was not a result of cell fusion between heparanase expressing host-derived cells and heparanase-negative transformed cells. This conclusion was based on the fact that both the in vitro maintained, heparanase-negative as well as the in vitro passaged, heparanase-positive cells exhibited a similar membrane and molecular market profile.

Asunto(s)

RESUMEN

Halobacterium volcanii mutants that are resistant to the dihydrofolate reductase inhibitor trimethoprim contain DNA sequence amplifications. This paper describes the cloning and nucleic acid sequencing of the amplified DNA sequence of the H. volcanii mutant WR215. This sequence contains an open reading frame that codes for an amino acid sequence that is homologous to the amino acid sequences of dihydrofolate reductases from different sources. As a result of the gene amplification, the trimethoprim-resistant mutant overproduces dihydrofolate reductase. This enzyme was purified to homogeneity using ammonium sulfate-mediated chromatographies. It is shown that the enzyme comprises 5% of the cell protein. The amino acid sequence of the first 15 amino acids of the enzyme fits the coding sequence of the gene. Preliminary biochemical characterization shows that the enzyme is unstable at salt concentrations lower than 2 M and that its activity increases with increase in the KCl or NaCl concentrations.

Asunto(s)

RESUMEN

Several pathogenic strains of Escherichia coli were isolated from chickens and turkeys with severe colisepticemia. Electron microscopic examination showed that all these strains had thin pili (fimbriae) when grown at 37 C but not at 18 C. These pili facilitated adherence of the bacteria to chick tracheal epithelial cells both in vitro and in vivo. The role of these pili in pathogenicity was examined by comparing chicks infected intratracheally with piliated bacteria and chicks infected with non-piliated bacteria. The presence of adherence pili on the infecting bacteria affected both the number of chicks that developed disease and the severity of the disease.

Asunto(s)